Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies

NCT00481871 is registered in ClinicalTrials.gov with Acrotech Biopharma Inc. as lead sponsor.

NCT NCT00481871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00481871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies
Lead sponsor
Acrotech Biopharma Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2007
Completion date
August 31, 2011
Enrollment
119 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, hodgkin's lymphoma, peripheral t-cell lymphoma, relapsed or refractory lymphoproliferative malignancies, waldenstrom's macroglobulinemia